mucosal defence
Recently Published Documents


TOTAL DOCUMENTS

67
(FIVE YEARS 0)

H-INDEX

22
(FIVE YEARS 0)

2017 ◽  
Vol 23 (3) ◽  
pp. 426 ◽  
Author(s):  
Richard Shore ◽  
Håkan Björne ◽  
Yoko Omoto ◽  
Anna Siemiatkowska ◽  
Jan-Åke Gustafsson ◽  
...  

2016 ◽  
Vol 1 (10) ◽  
Author(s):  
Jumpei Sasabe ◽  
Yurika Miyoshi ◽  
Seth Rakoff-Nahoum ◽  
Ting Zhang ◽  
Masashi Mita ◽  
...  

2015 ◽  
Vol 6 (3) ◽  
Author(s):  
Pragya Singhal

Background: : Acid peptic disease is the condition in which there is either excessive secretion of acid and pepsin or a weakened stomach mucosal defence, which is responsible for damage to the delicate mucosa and the lining of the stomach, oesophagus and duodenum resulting in ulceration.Parinama shoola in Ayurveda is comparable with Acid peptic disease.Aim of study: The Aim of the study is to evaluate and compare the effect of indigenous compound drugs (Shatavari mandoor and Pippali ghrita) in uncomplicated cases of Parinam shoola.Methods:  This is a prospective, open labelled, randomised clinical trial. A total of 31 patients suggestive of features of Parinama Shoola (acid peptic disorder) were enrolled and were randomly divided in two groups- 12 patients were enrolled in group A and were given trial drug Shatavari mandoor,19 patients were enrolled in group B and were given trial drug Pippali ghrita. Duration of study was 3 months.Results: Individually both groups showed statistically significant improvement in clinical symptoms i.e. pain in abdomen, epigastric burning, nausea, flatulence, loss of appetite and constipation (p<0.01), but the mean reduction in the symptoms of group A (Shatavari mandoor group) is more than group B (Pippali ghrita group).Conclusion: Both trial drugs are effective in the treatment of Parinama shoola. Shatavari mandoor is more effective in the treatment of Parinam shoola in comparison to Pippali ghrita. 


2015 ◽  
Vol 42 (7) ◽  
pp. 802-817 ◽  
Author(s):  
P. Pavlidis ◽  
N. Powell ◽  
R. P. Vincent ◽  
D. Ehrlich ◽  
I. Bjarnason ◽  
...  

Author(s):  
Sir Peter Gluckman ◽  
Mark Hanson ◽  
Chong Yap Seng ◽  
Anne Bardsley

Probiotics are live, non-pathogenic commensal microorganisms with beneficial effects on the host organism; they improve and/or maintain intestinal flora balance by suppressing and displacing harmful bacteria. Prebiotics are nondigestible food components that stimulate growth or activity of these beneficial intestinal bacteria. Such microorganisms form an integral part of the intestinal mucosal defence system and are important for the development and maturation of the infant#amp;#x2019;s gastrointestinal tract. Maternal ingestion of probiotics and prebiotics from dietary sources during pregnancy, or by the infant at weaning, may enhance the development and maturation of the neonatal gastrointestinal tract. Probiotic foods may also help control insulin resistance and the development of gestational diabetes.


2014 ◽  
Vol 28 (S1) ◽  
Author(s):  
Taolang Li ◽  
Xuemei Liu ◽  
Anurag Singh ◽  
Brigitte Riederer ◽  
Gerolf Gros ◽  
...  

2014 ◽  
Vol 211 (1) ◽  
pp. 17-19 ◽  
Author(s):  
H. Ishiguro
Keyword(s):  

PLoS ONE ◽  
2012 ◽  
Vol 7 (4) ◽  
pp. e35196 ◽  
Author(s):  
Rory Blackler ◽  
Stephanie Syer ◽  
Manlio Bolla ◽  
Ennio Ongini ◽  
John L. Wallace
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document